These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 20664466)
1. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Salt E; Frazier SK Orthop Nurs; 2010; 29(4):260-75. PubMed ID: 20664466 [TBL] [Abstract][Full Text] [Related]
2. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. van den Bemt BJ; van den Hoogen FH; Benraad B; Hekster YA; van Riel PL; van Lankveld W J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906 [TBL] [Abstract][Full Text] [Related]
3. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis. Kim G; Barner JC; Rascati K; Richards K Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313 [TBL] [Abstract][Full Text] [Related]
4. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis. McCulley C; Katz P; Trupin L; Yelin EH; Barton JL J Rheumatol; 2018 Dec; 45(12):1636-1642. PubMed ID: 30219761 [TBL] [Abstract][Full Text] [Related]
5. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil. Acurcio FA; Machado MA; Moura CS; Ferre F; Guerra AA; Andrade EI; Cherchiglia ML; Rahme E Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1489-96. PubMed ID: 26814681 [TBL] [Abstract][Full Text] [Related]
6. Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy. Petry L; Zuckerman AD; DeClercq J; Choi L; Lynch B; Saknini M J Manag Care Spec Pharm; 2023 Jul; 29(7):732-739. PubMed ID: 37404072 [No Abstract] [Full Text] [Related]
7. [Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis]. Chrzanowska A; Batko B; Hajdyła-Banaś I; Banaś T; Krezelok M; Ludwin A Przegl Lek; 2014; 71(4):199-203. PubMed ID: 25141578 [TBL] [Abstract][Full Text] [Related]
8. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. Kumar K; Raza K; Nightingale P; Horne R; Chapman S; Greenfield S; Gill P BMC Musculoskelet Disord; 2015 Dec; 16():396. PubMed ID: 26714853 [TBL] [Abstract][Full Text] [Related]
9. Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. Voshaar M; Vriezekolk J; van Dulmen S; van den Bemt B; van de Laar M BMC Musculoskelet Disord; 2016 Oct; 17(1):442. PubMed ID: 27769224 [TBL] [Abstract][Full Text] [Related]
10. Adherence to synthetic disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the OBSERVAR Study. Juan Mas A; Castañeda S; Cantero Santamaría JI; Baquero JL; Del Toro Santos FJ; Reumatol Clin (Engl Ed); 2019; 15(5):264-270. PubMed ID: 29289700 [TBL] [Abstract][Full Text] [Related]
11. Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis. Voshaar MJH; van den Bemt BJF; van de Laar MAFJ; van Dulmen AM; Vriezekolk JE BMC Health Serv Res; 2022 Jan; 22(1):62. PubMed ID: 35022034 [TBL] [Abstract][Full Text] [Related]
12. Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients. Oshotse C; Zullig LL; Bosworth HB; Tu P; Lin C Prev Chronic Dis; 2018 Oct; 15():E127. PubMed ID: 30339772 [TBL] [Abstract][Full Text] [Related]
13. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. van den Bemt BJ; Zwikker HE; van den Ende CH Expert Rev Clin Immunol; 2012 May; 8(4):337-51. PubMed ID: 22607180 [TBL] [Abstract][Full Text] [Related]
14. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. Kelly A; Tymms K; Tunnicliffe DJ; Sumpton D; Perera C; Fallon K; Craig JC; Abhayaratna W; Tong A Arthritis Care Res (Hoboken); 2018 Apr; 70(4):525-532. PubMed ID: 28732151 [TBL] [Abstract][Full Text] [Related]
15. Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe? Wong PK Rheumatol Int; 2016 Nov; 36(11):1535-1542. PubMed ID: 27665289 [TBL] [Abstract][Full Text] [Related]
16. Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study. Balsa A; García de Yébenes MJ; Carmona L; Ann Rheum Dis; 2022 Mar; 81(3):327-334. PubMed ID: 34844924 [TBL] [Abstract][Full Text] [Related]
17. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis. Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782 [TBL] [Abstract][Full Text] [Related]
18. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Grijalva CG; Chung CP; Arbogast PG; Stein CM; Mitchel EF; Griffin MR Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386 [TBL] [Abstract][Full Text] [Related]
19. Adherence to biologic DMARD therapies in rheumatoid arthritis. Koncz T; Pentek M; Brodszky V; Ersek K; Orlewska E; Gulacsi L Expert Opin Biol Ther; 2010 Sep; 10(9):1367-78. PubMed ID: 20681888 [TBL] [Abstract][Full Text] [Related]
20. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. Homer D; Nightingale P; Jobanputra P Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]